 At day 30, fondaparinux significantly reduced the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by 14% (p=0.008
fondaparinux 2.5 mg once daily
unfractionated heparin
death or recurrent myocardial infarction  in patients who received no reperfusion therapy or a thrombolytic agent